Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 8-K (Current Report)
Report Date: August 10, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The Company announced financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in the source text:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the announcement of Q2 2026 results but does not include specific commentary, guidance, or outlook details within the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Unusual Items: No unusual items are described in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash position figures.
- Verify year-over-year and quarter-over-quarter performance metrics not included in this summary.
- Check for updated clinical trial milestones or regulatory developments typically included in the full press release.
- Confirm liquidity status and cash runway projections provided in the full announcement.